Accordingly, our data suggested that BTKi-induced downregulation of DGAT2, ENPP2, SCD and ACACA might result in LD accumulation inhibition, which trigger modest MCL-cell death at least partially, and such findings provide a new evidence that targeting the lipid metabolism pathway might be a strategy to treat MCL, or other B-cell malignancies, which deserves further studies. This evidence concerns the gene SCD and mantle cell lymphoma.